Lithium Ion

Lithium Ion

SCHEMBL3423635

Cn1c(CC(=O)[O-])nc2c(C(F)(F)F)cccc21.[Li+]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.40
NTRK1 P04629 2/20 0.39
NTRK2 Q16620 2/20 0.39
NR1H2 P55055 3/20 0.38
NR1H3 Q13133 3/20 0.38
GRM2 Q14416 3/20 0.37
DRD4 P21917 1/20 0.37
CXCR3 P49682 1/20 0.36
DRD3 P35462 1/20 0.36
PTGES O14684 2/20 0.36
HSD11B1 P28845 1/20 0.36
AKT1 P31749 1/20 0.35
RORC P51449 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MAPT P10636 1/20 0.34
PDE10A Q9Y233 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3423633 0.85 PPARG (0.43) PPARGNTRK1NTRK2NR1H2NR1H3
SCHEMBL3426153 0.81 NR1H2 (0.42) PPARGNTRK1NTRK2NR1H2NR1H3
SCHEMBL26375284 0.70 CYP1A2 (0.47) NR1H2NR1H3GRM2HSD11B1PDE10A
Lithium Ion SCHEMBL3367542 0.69 CHEK1 (0.44) PTGES
SCHEMBL21555501 0.69 HSD11B1 (0.41) NTRK1NTRK2GRM2HSD11B1PDE10A
SCHEMBL15780474 0.68 MAPT (0.37) PPARGNR1H2NR1H3GRM2DRD3
SCHEMBL24910306 0.67 NR1H2 (0.47) NR1H2NR1H3GRM2DRD4HSD11B1
SCHEMBL900721 0.66 HSD11B1 (0.54) NR1H2NR1H3HSD11B1MAPTPDE10A
SCHEMBL12362586 0.66 PPARG (0.40) PPARGHDAC6MAPT
SCHEMBL1271724 0.63 NR1H2 (0.54) PPARGNR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696205-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2010-04-13 US disclosed
US-20080108678-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-7291615-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-06 US disclosed
US-20040235836-A1 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235836-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCL2 PPARG 1236/4885NTRK1 3322/4885NTRK2 2270/4885
US-20080108678-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCL11, CCL2, CCR1 PPARG 1021/4885NTRK1 3128/4885NTRK2 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.